PagerDuty's stock jumps on strong earnings, sales
PagerDuty Inc.'s (PD) stock initially jumped 8% in extended trading Thursday after the enterprise-software company reported quarterly results that edged analyst revenue and earnings estimates. PagerDuty reported a fiscal-third-quarter net loss of $13.1 million, or 16 cents a share, compared with a net loss of $32.8 million, or 36 cents a share, in the same quarter a year ago. Adjusted earnings were 20 cents a share. Revenue was $108.7 million, up 15% from $94.2 million in the same quarter a year ago. Analysts surveyed by FactSet had expected on average net earnings of 14 cents a share on revenue of $107.7 million. "This has been a challenging environment, with customers cautious toward renewals," PagerDuty Chief Financial Officer Howard Wilson said in an interview. "But we excelled in customer acquisitions and expansion with more multiyear deals." For the fourth quarter, the company expects revenue of between $109.5 million and $111.5 million. FactSet analysts are forecasting $110.9 million. Shares of PagerDuty have tumbled 18% this year, while the broader S&P 500 index has increased 19%.
-Jon Swartz
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-30-23 1616ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks